SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.480
-0.070 (-4.52%)
At close: Mar 28, 2025, 4:00 PM
1.516
+0.036 (2.45%)
Pre-market: Mar 31, 2025, 8:08 AM EDT
SAB Biotherapeutics Stock Forecast
SABS's stock price has decreased by -64.93% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 12.4, with a low estimate of 6.00 and a high estimate of 25. The average target predicts an increase of 737.84% from the current stock price of 1.48.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 29, 2025.
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +1,589.19% | Jan 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +305.41% | Jan 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +1,589.19% | Nov 7, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +643.24% | Oct 9, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $12 | Buy | Reiterates | $12 | +710.81% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
1.35M
from 2.24M
Decreased by -39.66%
Revenue Next Year
1.02M
from 1.35M
Decreased by -24.50%
EPS This Year
-3.75
from -7.64
EPS Next Year
-3.05
from -3.75
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.8M | 2.1M | 3.2M | |||
| Avg | 1.4M | 1.0M | 1.3M | |||
| Low | 1.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -20.3% | 55.4% | 208.8% | |||
| Avg | -39.7% | -24.5% | 25.0% | |||
| Low | -47.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.66 | -1.02 | -1.04 |
| Avg | -3.75 | -3.05 | -2.70 |
| Low | -3.85 | -5.20 | -3.95 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.